Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and costly. Programs can stall due to material–drug compatibility issues, inconsistent release profiles, tooling-related variability, and scale-up challenges between prototyping and GMP-capable small-batch production. Combined with evolving regulatory expectations around extractables and leachables, as well as stringent cleanroom requirements, these obstacles can lead to costly redesigns, delayed timelines, and missed market opportunities.
In this webinar, H&T Presspart and PlasTech Engineering will explore the sustained release device landscape from early feasibility through to small-batch commercialization. We will begin by examining key market drivers and delivery device formats before discussing the development expertise required to de-risk programs. Topics will include defining critical-to-quality attributes, selecting and qualifying materials for performance and stability, and aligning device design with manufacturing requirements.
We will share practical methods and case-based lessons on development, tooling and manufacturing: designing and validating molds for consistency, building a scalable process path from prototype to controlled, GMP small-batch production. You’ll learn how to align design, polymer choice, tooling strategy, and production environment requirements to reduce variability, prevent late-stage surprises, and shorten time-to-clinic and time-to-market.
If you are developing or scaling a sustained release device and want actionable guidance to avoid common pitfalls, register now to secure your spot. Join us to equip your team with proven approaches that connect early development decisions to reliable small-batch commercialization.
Key Learning Objectives
- Sustained release market overview
- Development case study
- Material choices and their implications for release and stability
- Tooling challenges & GMP requirements for small batch commercilisation
